Latest Neuroscience News

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

Cogstate Ltd has upgraded its FY25 financial guidance, projecting a 20-24% revenue increase and nearly doubling profit before tax compared to last year.

Patrys Limited has raised $358,362 through a share placement and announced significant board changes, including the appointment of Dr Anton Uvarov and Mr Peter Christie, alongside making the CEO role redundant.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.